Douglas Sidell

Douglas Sidell

Auto-generated profile, based on publicly available information

Douglas Sidell

Stanford University School of Medicine Palo Alto California USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
DSDouglas R. Sidell
Douglas R. Sidell
IKIrene A. Kim
Irene A. Kim
TCTumaini R. Coker
Tumaini R. Coker
CMCandice Moreno
Candice Moreno
NSNina L. Shapiro
Nina L. Shapiro

5 August 2013 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
DSDouglas Sidell
Douglas Sidell
NSNina L. Shapiro
Nina L. Shapiro
NBNeil Bhattacharyya
Neil Bhattacharyya

14 March 2014 in Annals of Otology, Rhinology & Laryngology
Verified
Journal Article
Closed access
DSDouglas R. Sidell
Douglas R. Sidell
MNMichel Nassar
Michel Nassar
RCRobin T. Cotton
Robin T. Cotton
SZSteven M. Zeitels
Steven M. Zeitels
AAAlessandro de Alarcon
Alessandro de Alarcon
Objectives: We review and report the use of high-dose bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP) in pediatric patients. Methods: We included all patients with pediatric-onset RRP who underwent bevacizumab (25 mg/mL) injections by a single practitioner. A series of 5 consecutive subepithelial injections were administered at 4- to 6-week intervals with concomitant 532 nm KTP laser ablation. The lesions were staged according to the Derkay staging system. The outcomes included pretreatment and posttreatment Derkay scores, the time interval between procedures, and voice outcomes. The demographic data extracted included sex, age at diagnosis, and current age. Results: Nine patients were included in this study, with 1 patient lost to follow-up; their median age was 8 years (range, 3 to 21 years). The mean bevacizumab dose was 14.25 mg (range, 5 to 45 mg). There was a median Derkay score of 11.5 (range, 4 to 23) at the time of diagnosis and a median 58% improvement following therapy. All patients demonstrated an increased time interval between injections, for a median improvement of 2.05× (range, 1.6× to 3.25×). Conclusions: Evidence exists in support of vascular endothelial growth factor as an important factor in the development of RRP. Although some variability in response is demonstrated by this study, high-dose bevacizumab appears to yield promising results for pediatric patients with RRP.

8 March 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MRMichael Rutter
Michael Rutter
CHCatherine K. Hart
Catherine K. Hart
AAAlessandro de Alarcon
Alessandro de Alarcon
SDSam J. Daniel
Sam J. Daniel
SPSanjay R. Parikh
Sanjay R. Parikh
DSDouglas R. Sidell
Douglas R. Sidell

31 March 2015 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
KBKarthik Balakrishnan
Karthik Balakrishnan
NBNancy Bauman
Nancy Bauman
RCRobert H. Chun
Robert H. Chun
DDDavid H. Darrow
David H. Darrow
JGJ. Fredrik Grimmer
J. Fredrik Grimmer
RERavindhra G. Elluru
Ravindhra G. Elluru

27 August 2018 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
KBKarthik Balakrishnan
Karthik Balakrishnan
DSDouglas R. Sidell
Douglas R. Sidell
NBNancy M. Bauman
Nancy M. Bauman
GBGaston F. Bellia‐Munzon
Gaston F. Bellia‐Munzon
RBR. Paul Boesch
R. Paul Boesch
RCRobin T. Cotton
Robin T. Cotton